Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of this population in which genetic patterns could be involved in the etiology of essential hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: sigma-tau i.f.r. S.p.A.

Criteria

Inclusion Criteria:

• Patients with grade 1 or 2 of essential hypertension

• Less than 3 risk factors (age > 55 if male, smoking, dyslipidemia, family history of CV disease occurring before 55 years in men and 65 in women

• Naive patients or currently on monotherapy or one combination tablet

• SBP between 140 and 169 mmHg

Exclusion Criteria:

• Atrial fibrillation or left or right VBBB

• Left ventricular hypertrophy

• Significant renal or hepatic disease

• Obesity > 30kg/m2

• Diabetes mellitus